Slides
Page 1
RBC Fireside WebcastBrent JonesMay 20, 2025
Page 2
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of1934, and are subject to the safe harbor created thereby under the Private SecuritiesLitigation Reform Act of 1995. All statements other than statements of historical factincluded in this presentation are forward-looking statements. Forward-lookingstatements discuss our current expectations and projections relating to our financialcondition, results of operations, plans, including our cost transformation initiative,objectives, future performance and business. These statements may be preceded by,followed by or include the words “aim,” “anticipate,” “assumption,” “believe,”“continue,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “likely,”“long-term,” “near-term,” “objective,” “opportunity,” “outlook,” “plan,” “potential,”“project,” “projection,” “prospects,” “seek,” “target,” “trend,” “can,” “could,” “may,”“should,” “would,” “will,” the negatives thereof and other words and terms of similarmeaning.Forward-looking statements are inherently subject to risks, uncertainties andassumptions; they are not guarantees of performance. You should not place unduereliance on these statements. We have based these forward-looking statements on ourcurrent expectations and projections about future events. Although we believe thatour assumptions made in connection with the forward-looking statements arereasonable, we cannot assure you that the assumptions and expectations will prove tobe correct. Factors that could contribute to these risks, uncertainties and assumptionsinclude, but are not limited to, the factors described in “Risk Factors” in our most recentannual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such riskfactors may be updated from time to time in our periodic filings with the SEC. Allforward-looking statements attributable to us or persons acting on our behalf areexpressly qualified in their entirety by the foregoing cautionary statements. In addition,all forward-looking statements speak only as of the date of this presentation. Weundertake no obligations to update or revise publicly any forward-looking statements,whether as a result of new information, future events or otherwise other than asrequired under the federal securities laws. Non-GAAP financial measures DisclaimerTo evaluate our performance, we monitor a number of key indicators at theconsolidated level and, in certain cases, at the segment level. As appropriate, wesupplement our results of operations determined in accordance with U.S. generallyaccepted accounting principles (“GAAP”) with certain non-GAAP financial measuresthat are used by management, and which we believe are useful to investors, assupplemental operational measures to evaluate our financial performance. Thesemeasures should not be considered in isolation or as a substitute for reported GAAPresults because they may include or exclude certain items as compared to similarGAAP-based measures, and such measures may not be comparable to similarly-titledmeasures reported by other companies. Rather, these measures should be consideredas an additional way of viewing aspects of our operations that provide a morecomplete understanding of our business. We do not provide GAAP financial measureson a forward-looking basis because we are unable to predict with reasonablecertainty and without unreasonable effort items such as acquisition-related charges,the costs associated with integrating acquired businesses, the timing and amount offuture restructuring actions, and the early retirement of debt.We strongly encourage investors to review our consolidated financial statements intheir entirety and not rely solely on any one, single financial measure. See “Use of Non-GAAP Financial Measures” in our accompanying press release. A reconciliation of non-GAAP measures is included in the supplemental disclosures package on our investorrelations website atir.avantorsciences.com.2Trademarks are owned by Avantor, Inc. or its subsidiaries, unless otherwise noted. ©2025 Avantor, Inc. All rights reserved.
Page 3
Avantor at a glanceComprehensive portfolio of high-quality laboratory consumables, equipment, services and digital solutionsMission critical, high-purity materials and solutionsLaboratory Solutions Bioscience Production 2024Bioprocessing SiliconesApplied SolutionsAdvanced Lab ServicesTotal Science SolutionsLaboratory Specialty Products ~1/3 of revenue, 25.7% margin1~2/3 of revenue, 13.0% margin1Revenue Margin1 1. Adjusted operating income margin3
Page 4
Leading provider of mission-critical, high-purity materials and solutionsStrong foundation in bioscience production•Process ingredients & excipients•Single use systems and integrated solutions •Controlled environment consumablesBioprocessing (67%)•NuSil ultra-high purity medical and aerospace grade silicone formulationsSilicones (17%) Applied Solutions (16%) Total Revenue = Proprietary Content •High margin segment with foundation of solid historical growth•Highly recurring revenue driven by regulatory and quality expertise for tightly regulated markets•Attractive growth profile with strong end market fundamentals, rising approval levels, increasing production levels and order book momentum•Electronic Materials-proprietary formulated solutions for semiconductor manufacturing•Proprietary chemicals for healthcare, biopharma, and diagnostic applications•Chemicals and PPE for industrial applications4All figures reflect FY2024 financial performance. Percentages reflect percent of segment revenue.
Page 5
UPSTREAM DOWNSTREAMFORMULATION FILL & FINISH•Amino acids•Carbohydrates•Vitamins•Biological buffers•Microbial processes: reagents to stimulate cell growth (IPTG)•Mineral salts•Biological buffers•Surfactants •Chromatography resins (Protein A, L; IEX, HIC)•J.T. Baker® Viral Inactivation Solution•Excipients:•Amino Acids•Antioxidants•Carbohydrates•Biological buffers•Mineral salts•Surfactants Process Ingredients & Excipients 44% of revenueSingle-use Systems & Integrated Solutions26% of revenue Media & SupplementsBuffers & Salts Buffers & Salts ExcipientsSugarsAdditivesPre-processing / Prep | PPE | Production / Processing | Cleaning/Disinfection | Environmental Monitoring Full-service, end-to-end solutions that safeguard cleanroom integrity Controlled Environment Consumables30% of revenue Tubes & Connectors Peristaltic Pump Mixing System Tank Liners3D Liquid Bag Fluid handling: Single-use assemblies and Masterflex®peristaltic pumps, tubing Single use: Media mixing containers, 2D & 3D bag assemblies, tank liners, sterile fluid connections, aseptic sampling System solutions: scalable magnetic mixing/process systems, pumps Our bioprocessing offerings span the full production workflow Buffers & Salts SugarsAdditives PurificationHydrated solutions:(RTU or concentrates)Downstream process optimization solutions5All figures represent FY2024 financial performance. Percentages reflect percent of bioprocessing revenue.
Page 6
Summary Global leader in laboratory solutions Bioscience production segment provides mission-critical materials and solutions Attractive bioprocessing portfolio driven by specification positions and throughput Cost transformation is driving conversion and margins6
Page 7
Powering science at .